



ALMA MATER STUDIORUM  
UNIVERSITÀ DI BOLOGNA  
Gualtiero Gandini



MYLAV  
Laboratorio La Vallées



**"Clinical and therapeutic approach to the idiopathic epileptic dog"**

1

---

---

---

---

---

---

---

---

**"Clinical and therapeutic approach to the idiopathic epileptic dog "**



*... what's the best way to tell the whole story?*

2

---

---

---

---

---

---

---

---

**«Consensus statement»**




Guidelines published by a group of acknowledged experts  
aimed to standardize the approach to a specific problem

3

---

---

---

---

---

---

---

---



4

---

---

---

---

---

---

---

---

## Goal of the lecture:

Provide a comprehensive and rational clinical approach to the idiopathic epileptic dog

### INDEX:

1. The owner's perspective
2. What is Epilepsy?
3. What happens during a seizure?
4. Idiopathic or structural Epilepsy?
5. Goals of the treatment?
6. When starting treatment?
7. Which drug should I use first?
8. It is not doing well ... what can I do?



5

---

---

---

---

---

---

---

---

1.



## The owner's perspective

6

---

---

---

---

---

---

---

---

### .... The owner's perspective ....



7

---

---

---

---


---

---

---

---

### .... My examination....



8

---

---

---

---

---

---

---

---

### The owner and the management of epilepsy

Taylor ↔ Clothes factory



9

---

---

---

---

---

---

---

---

2.



## What is Epilepsy?

10

### DEFINITIONS

**Epilepsy:** from Greek "epilambanein" (being attacked, possessed), referred to people affected by the "holy disease"

**"Epilepsy"** - chronic brain disorder characterized by the *recurrence of epileptic seizures*" (Fisher et al., 2005)

**"Epileptic Seizure"** is the transient manifestation of clinical signs reflecting an *abnormal, excessive and/or hypersynchronous neuronal electrical activity in the brain*" (Fisher et al., 2005)



11


### Classification of Seizures :

According to the frequency

- **Single seizure**  
(Interval more than 24 h)
- **Cluster of seizures**  
(Interval less than 24h)
- **Status Epilepticus**  
(seizures lasting more than 5 minutes or 2 or more seizures in 30 minutes without full recovery)



12



13

## Idiopathic Epilepsy

**Aetiology ???**

{ Genetic  
Suspected genetic  
Of Unknown origin

Idiopathic Epilepsy in the dog is most probably  
a genetic hereditary disease



**"CHANNELOPATHY"**

The diagnosis of Idiopathic Epilepsy is "by exclusion"

14

## Idiopathic Epilepsy

### DIAGNOSIS:

*International Veterinary Epilepsy Task Force (2015)*

#### Tier I confidence level:

- History of ≥ 2 epileptic seizures
- Age between six months and six years
- Normal neurological examination
- CBC, Blood profile and urinalysis normal

#### Tier II confidence level:

- Tier I prerequisite
- Normal pre- & post prandial bile acids
- Normal advanced diagnostic imaging (CT or MRI)
- Normal cerebrospinal fluid (CSF) examination

#### Tier III confidence level:

- Tier II prerequisite
- EEG tracing compatible with Epilepsy

15


3.




What happens  
during a seizure?

16

An earthquake



An epileptic seizure



17

### Physiopathology



INHIBITION

EXCITATION




NORMAL BRAIN

EPILEPTIC BRAIN



18



19

---

---

---

---

---


---

---

---

## Physiopathology

- Abnormal hypersynchronous activity
- Imbalance between excitatory and inhibitory systems
- Lack of adequate inhibitory feed-back



Propagation

Epileptic seizure!

20

---

---

---

---

---

---



---

---


## Classification of epileptic seizures

According to the clinical presentation

FOCAL

FOCAL with  
secondary  
generalization

GENERALIZED



21

---

---

---

---

---

---

---

---

Focal seizure



22

---

---

---

---

---

---

---

Focal seizure



23

---

---

---

---

---

---

---

## Generalized tonic-clonic seizure



3 Phases :

- Prodromal Phase

→ - (Aura) Ictal phase

- Post-ictal phase



24

---

---


---

---

---

---

---



25

---

---

---

---

---

---

---

---



26

---

---

---

---

---

---

---

---



27

---

---

---

---

---

---

---

---

## Post-ictal phase

Variable duration: → few minutes to several hours

Neurologic Signs due to neuronal exhaustion

(cell damage due to hypoxia, acidosis and failure of the membrane pumps)

- Amaurosis (central blindness)
- Ataxia
- Disorientation
- Polyphagia
- Vomiting
- Temporary various neurological deficits



28

---

---

---

---

---

---

---

Generalized tonic-clonic seizure



29

---

---

---


---

---

---

---

post-ictal  
phase



30

---

---

---

---

---

---


---

4.




## Idiopathic or Structural epilepsy?

31



32




33

## PHYSICAL EXAMINATION

Idiopathic or Secondary Epilepsy?

### NEUROLOGICAL EXAMINATION!!!

(after at least 48 hours from the last seizure)



34

---

---

---

---

---

---

---

---

## PHYSICAL EXAMINATION

Scenario: NEUROLOGIC DEFICITS

"short cut":



EPILEPTIC SEIZURE



CEREBRAL CORTEX



FOREBRAIN



35

---

---

---

---

---

---

---

---

## Forebrain syndrome

POSSIBLE CLINICAL SIGNS:

### Seizures and...

- ◊ behavioural abnormalities
- ◊ Gait ± normal
- ◊ Menace response deficit
- ◊ Proprioceptive deficits



36

---

---

---

---

---

---

---

---

An example to summarize



"ARTU", BOXER, m, 5y, 31kg

37

"ARTU", BOXER, m, 5y, 31kg

### HISTORY

- ◊ Artu was referred because since approximately **THREE MONTHS** is experiencing **generalized tonic-clonic seizures**
- ◊ Seizures had an initial frequency of **one every 15 days**, and, in the last month, **one per week**.
- ◊ the referring vet prescribed **Phenobarbital 3 mg/kg Bid**, stopped by the owner after ten days due to the excessive sedation of the dog
- ◊ Artu has a normal vaccination plan, is on pet food diet and lives in urban environment.

38

"ARTU", BOXER, m, 5y, 31kg



39

"ARTU", BOXER, m, 5y, 31kg



40

---

---

---

---

---

---

---

---

"ARTU", BOXER, m, 5y, 31kg



41

---

---

---

---

---

---

---

---

"ARTU", BOXER, m, 5y, 31kg



42

---

---

---


---

---

---

---

---



43

---

---

---

---


---

---

---

---

### Clinical differential diagnoses



44

---

---

---

---

---


---

---

---

### Diagnostic Work-up

- ✓ CBC & ematobiochemical profile
- ✓ bile acids & blood ammonia
- ✓ thorax X-ray/abdominal US
- ✓ ADVANCED DIAGNOSTIC IMAGING
  - Computed Tomography (CT)
  - Magnetic Resonance Imaging (MRI)
- ✓ Cerebrospinal fluid exam



45

---

---

---

---

---

---

---

---

## Everything ok?



46

---

---

---

---

---

---

---

---



*\*Take home message*

- Epilepsy: different severity and phenotype! ...«umbrella»...
- You and the owner are the same team:  
**GOOD COMMUNICATION: make him aware of what Epilepsy is**  
*In term of expectations, limitations, necessity of periodic controls*
- Pathogenesis → *Imbalance between excitatory and inhibitory mechanisms*
- Type of seizures: focal and generalized
- Idiopathic and structural Epilepsy
- structural Epilepsy: epileptic seizures and forebrain signs  
*Behavioural abnormalities*  
*Proprioceptive deficits*  
*Abnormal menace response*
- Complete diagnostic work-up



47

---

---

---

---

---

---

---

---

# 5.



## Goals of the treatment?

48

---

---

---

---

---

---

---

---

## General principles and goals

- **GOAL: REDUCTION** (not elimination!!!) of the frequency and severity of the seizures
- Chronic therapy maintained for the whole life of the patient and possible relevant side-effects
- Clear and complete communication with the owner:
  - . realistic expectations on therapeutic effects
  - . awareness of possible side effects
  - . Necessity of periodic medical control



49

---

---

---

---

---



---

---

---

**Epilepsy treatment**

Tailor ↔ Clothes factory

**PRIORITIES:**

FIRST: Control Seizures  
SECOND: Control Side-effects

50

---

---

---

---

---

---

---

---

6



### When Should Treatment Be Started?

The decision to start AED treatment is based on a number of factors, including etiology, risk of recurrence, seizure type, tolerability, and adverse effects. Risk factors for seizure recurrence are not well established for cats and dogs. A number of relative risk factors

## When should treatment be started?

51

---

---

---

---

---


---

---

---

## When should treatment be started?

- Not possible to produce "cooking recipes"
- Normally treatment is started:
  - after that the diagnostic work up has excluded other causes;
  - after the confirmation of the **recurrence** of the seizures (at least **2 in 6 months**);
  - **Immediately**, in case of:
    - cluster seizures /status epilepticus
    - Structural epilepsy
- Choice of the drug and dosage depends upon the aggressiveness of epilepsy  
Consider: costs and potential side effects



52

7



### Which Drug Should Be Used First?

Selection of AED is based on a number of factors, including seizure type, efficacy, and tolerability. No evidence exists that any single AED provides a better outcome for adults with unprovoked epilepsy when early treatment is started in people.<sup>19</sup> Drug selection, therefore, is often based on tolerability in both people and dogs. The panel recommendations are summarized in Table 1.

## Which drug should I use first?

53

## Which drug should be used first?

Table 1. ACVIM panel recommendations of AED use, monitoring, and risk profile.

| Drug          | Monotherapy recommendation |       | Grade of ACVIM panel recommendation   |
|---------------|----------------------------|-------|---|
|               | Level                      | Grade |   |
| Phenobarbital | I                          | A     | 1 A: High recommendation and likely to be effective treatment<br>2 B: Moderate recommendation and most likely to be effective treatment<br>3 C: Low recommendation and may not be effective treatment<br>4 D: Not recommended for treatment and may be ineffective and/or dangerous |
| Bromide       | I                          | B     |   |
| Primidone     | III                        | D     |   |
| Imepitoin     | I                          | A     |   |
| Levetiracetam | IV                         | C     |   |
| Zonisamide    | III                        | C     |   |

### Phenobarbital and Imepitoin

"High recommendation and likely to be effective treatment, appropriately designed, controlled trials"

### Bromide

"Moderate recommendation and most likely to be effective treatment"

54

## Phenobarbital

First-line drug in the treatment of Epilepsy in the dog

### MECHANISM of ACTION:

Enhances the mechanisms of hyperpolarization and the stability of the cell membranes



### PHARMACOKINETICS

Liposoluble drug well absorbed after IV, IM and oral administration;

Metabolized in the liver → NO induction of liver enzymes!

Half-life time ~ 50 hours

"Steady state" ~ 15-20 days



55

---

---

---


---

---

---

---

---



56

---

---

---

---

---

---

---

---

## Phenobarbital

### DOSAGE

Initial dosage: 2,5 mg/kg PO BID

Monitoring plasma levels after two-three weeks:  
(therapeutic range 15-35 µg/ml)



### SIDE EFFECTS

Polyphagia  
Polyuria/Polydipsia  
Sedation  
Ataxia  
Hepatotoxicity???

Normally not recorded under  
35 µg/ml in healthy dogs

Check periodically (every 6 months) the  
liver function (test ALT, AST, SAP, **Bile**  
**acids, albumin, Cholesterol**)

57

---

---

---

---

---

---

---

---

## Imepitoin

First AED developed in veterinary medicine for the treatment of canine Epilepsy

### Strengths :

- Same efficacy as Phenobarbital
- less adverse effects

### Weakness:

- COST!

### MECHANISM of ACTION:

Partial agonist acting at the benzodiazepine recognition site of the GABA<sub>A</sub> receptor



### PHARMACOKINETICS:

short half-life time (~ 2 hours)  
Steady state achieved in ~ 2 days  
metabolized by liver (oxidation)

**DOSAGE:** 10–30 mg/kg BID

58

---

---

---

---

---

---

---

---



59

---

---

---

---

---

---

---

---

8

It is not doing well ...  
what can I do?



60

---

---

---

---

---

---

---

---

## Therapeutic failure

No benefit or  
seizures reduction frequency less than 50%

### 1. Wrong diagnosis:

1. signalment/ History?
2. neurological examination?
3. complete work-up?



### 2. Poor owner compliance:

1. goals: good communication?
2. wrong expectations?
3. drug regimen (i.e. TID)?
4. ....Just a bad owner...

- Refractory epilepsy
- Inappropriate dosages



61

## Therapeutic failure

No benefit or  
seizures reduction frequency less than 50%

what's the next step?

- MONITOR SERUM LEVELS (if on PB or Bromide treatment)
- Increase the dosage  
(depending on serum levels and side effects)
- think to associate another drug (and ask for the specialist advice)


62

## Therapeutic failure

WHAT CAN I DO?

(scenario « Phenobarbital »)

Inadequate dosage / inefficacy of the drug  
*monitor the plasma levels of the drug (PB : 15-35 µg/ml)*




63

## Therapeutic failure

### WHAT CAN I DO?

(scenario «Imepitoin»)



64

**Table 2. Qualified criteria recommendations for AED drug use.**

| Drug              | Indications  |                  |                       | Drug monitoring  | Cautions and risks                         | Initial dose                                       |
|-------------------|--------------|------------------|-----------------------|--|--|--|
|                   | Seizure type | Seizure etiology | Other                 |  |  |  |
| Phenobarbital     | All          | All              |                       | 2 and 6 weeks, qhs, or 2 weeks after dose change; Range: 15–35 µg/mL   | Hypotension; Idiosyncratic blood dyscrasia | 2.5 mg/kg q12h                                     |
| Add-on            | All          | All              |                       | Increases clearance of levetiracetam and ceftriaxone   | Neutrocytic dermatitis                     |  |
| Potassium Bromide | All          | Idiopathic       | Low initial frequency | 1 and 3 months, q12hs or 1 month after dose change; Range: 1000–2000 mcg/mL (tissue) or 800–2000 mcg/mL with phenobarbital | Pancreatitis; Scleritis; Ataxia            | 40 mg/kg/day                                       |
| Add-on            | All          | All              | Liver disease         |  |  |  |
| Imepitoin         | All          | Idiopathic       |                       |  |  | 15 mg/kg q12h                                      |
| Add-on            | All          | NR               |                       |  |  |  |
| Levetiracetam     | All          | All              | Liver disease         |  | Renal disease                              | 20 mg/kg qhs                                       |
| Add-on            | All          | All              |                       |  |  |  |
| Zonisamide        | All          | All              |                       | 2 and 3 months, qhs and 2 weeks after dose change; Range: 10–40 mcg/mL   | Idiosyncratic renal and hepatic disease    | 5 mg/kg q12h<br>7–10 mg/kg q12h with phenobarbital |
| Add-on            | All          | All              |                       |  |  |  |

NR = not recommended.

65

## Second-line AEDs

### Kalium Bromide

AED used in human medicine in the last century and then abandoned for its side effects on libido

Since the '80s used associated to Phenobarbital in refractory epilepsies or in hepatopatic patients.

#### MECHANISM of ACTION

Non completely understood. Apparently Br<sup>-</sup> ions are more effective than Cl<sup>-</sup> in the neuron cell membrane hyperpolarization



#### PHARMACOKINETICS

Very long half-life time (20–28 days); Steady-state achieved after 2–3 months

Eliminated by kidneys – NOT metabolized by the liver

66

## Second-line AEDs

### *Kalium Bromide*

#### DOSAGE

Initial dosage: 20–40 mg/kg/day PO

Monitoring plasma levels after two–three months:  
(therapeutic range 1–3 mg/ml)

#### SIDE EFFECTS



Polyphagia  
Polyuria/Polydipsia  
Sedation  
Ataxia  
*Acute pancreatitis??*



67



### *Levetiracetam*




- . Approved by FDA in 1999
- . Very well tolerated in human beings;
- . Very effective in treatment of human refractory epilepsy;
- . **Different mechanism of action:** Binds to synaptic vesicle protein (SV2A), influencing presynaptic neurotransmitter release
- . **Minimal hepatic metabolism** → 70–90% excreted unchanged in urines
- . Monotherapy at the same dosage
- . Cats: **dosage: 20 mg/kg TID per os**
- . Expensive



68

.... Wrong Localization.....



69

  
\*Take  
home message

- Therapy: when to start treatment?
- No cooking recipes – «tailoring» according to each patient
- «Consensus»: Phenobarbital and Imepitoin first line drugs
- Before changing the drug be sure it is NOT working!  
check Phenobarbitalemia and Bromuremia  
use the AED till the highest dosage
- Second line drug: Bromide and Levetiracetam
- Excessive adverse effects – priorities :  
FIRST: control seizures  
SECOND: control side effects



70

---

---


---

---

---

---

---



71

---

---

---

---

---

---

---